ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $23.00 price objective on the stock. D. Boral Capital’s target price would suggest a potential upside of 235.28% from the stock’s current price.

Other research analysts also recently issued reports about the stock. Jefferies Financial Group increased their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. HC Wainwright increased their target price on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. Finally, BTIG Research initiated coverage on shares of ImmunityBio in a research report on Thursday, March 12th. They issued a “buy” rating and a $13.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Trading Down 3.1%

Shares of NASDAQ:IBRX opened at $6.86 on Wednesday. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $12.43. The company’s 50 day moving average is $7.78 and its two-hundred day moving average is $4.46. The company has a market cap of $7.05 billion, a PE ratio of -18.05 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. As a group, equities research analysts expect that ImmunityBio will post -0.92 EPS for the current year.

Insider Buying and Selling at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the transaction, the director directly owned 2,925,821 shares in the company, valued at $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 501,967 shares of company stock worth $4,466,412 over the last three months. 69.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IBRX. Slow Capital Inc. purchased a new position in ImmunityBio during the 3rd quarter worth $25,000. Truist Financial Corp acquired a new stake in shares of ImmunityBio in the 3rd quarter worth $27,000. Swiss Life Asset Management Ltd acquired a new stake in shares of ImmunityBio in the 3rd quarter worth $27,000. WealthPlan Investment Management LLC acquired a new stake in shares of ImmunityBio in the 4th quarter worth $27,000. Finally, Diversify Advisory Services LLC acquired a new stake in shares of ImmunityBio in the 2nd quarter worth $27,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio says it submitted a comprehensive response to the FDA’s OPDP concerns, confirmed the TV ad was never aired, addressed the podcast issues and pledged tighter advertising oversight — a compliance step that could limit further regulatory damage. ImmunityBio Addresses FDA Correspondence
• Positive Sentiment: Some market coverage noted an immediate, modest rebound after the company’s compliance response (reports of a ~3% intraday uptick), suggesting short-term relief for investors who view the company’s corrective actions as credible. ImmunityBio Stock Gains 3%
• Positive Sentiment: At least one sell-side commentary (BTIG) remains constructive on IBRX despite the OPDP action, which may temper longer-term selling if commercial momentum and clinical data continue to support the story. ImmunityBio Faces FDA Warning, BTIG Stays Positive
• Neutral Sentiment: Coverage highlights the company’s stated compliance fixes alongside ongoing sales/expansion efforts; investors will watch whether operational performance offsets reputational/regulatory risk. IBRX Responds to FDA Warning
• Neutral Sentiment: Some analysts and outlets speculate shorter-term technical snapshots (e.g., whether the stock will “snap” a brief losing streak) and focus on upcoming data links for Anktiva; these are market-moving only if new data or guidance appears. IBRX Stock Set to Snap 2 Days of Losses?
• Negative Sentiment: Regulatory action sparked a major market reaction: headlines noted a sharp (~21%) prior share plunge after the FDA flagged potentially misleading efficacy claims for Anktiva — an event that materially increases reputational and litigation risk for the company. IBRX Shareholder Update – Hagens Berman
• Negative Sentiment: Multiple law firms have filed securities class actions or are soliciting lead-plaintiff applications alleging misleading statements about Anktiva; dozens of counsel notices cite a May 26, 2026 deadline to seek lead-plaintiff status — this concentrated litigation activity is a clear near-term negative for valuation and shareholder sentiment. ImmunityBio Securities Fraud Class Action – Kahn Swick

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.